The cells in question are mucosal-associated invariant T cells, commonly abbreviated as MAIT cells. These are unconventional T lymphocytes that recognize microbial metabolites presented by a molecule called MHC class I-related protein 1, or MR1. MAIT cells are abundant in the human liver, a location that makes them particularly relevant to hepatocellular carcinoma, and they are typically prized for their capacity to mount swift cytotoxic responses against bacteria and, potentially, against tumor cells. In the new study, published in the Journal of Translational Medicine, the researchers report that a distinct subpopulation of these cells, which they term stress-responsive MAIT cells or MAIT_SR cells, correlates strongly with the presence of microvascular invasion in patient tumors, and that these cells appear to orchestrate a peritumoral environment that favors immune escape and vascular spread.

To reach these conclusions, the team employed single-cell RNA sequencing on hepatocellular carcinoma specimens that were either positive or negative for microvascular invasion. This technique allows researchers to profile gene expression in thousands of individual cells, revealing the phenotypic landscape of the tumor microenvironment at unprecedented resolution. By integrating these single-cell data with multi-source bulk transcriptomic datasets and spatial transcriptomics, which maps gene expression onto intact tissue architecture, the investigators delineated the distinct stress-responsive phenotype of the MAIT cell population. The findings were then validated using flow cytometry, multiplex immunohistochemistry, and in vitro functional assays, providing multiple independent lines of evidence for the existence and behavior of this unusual cell subset.

What distinguishes the MAIT_SR cells from their non-stress-responsive counterparts is a striking molecular signature. The stress-responsive subset exhibited elevated expression of heat shock proteins, the molecular chaperones that cells deploy when confronted with physiological stress, but at the same time showed diminished cytotoxicity, meaning they had lost much of their tumor-killing capacity. Pathway enrichment analyses revealed that these cells were characterized by heightened activity in hypoxia signaling, glycolysis, and NF-κB signaling, all of which are hallmarks of cells adapting to the hostile, oxygen-poor, nutrient-competitive conditions that prevail within and around solid tumors. In other words, the very stressors generated by the tumor appear to reprogram these immune cells, converting potential anti-tumor allies into components of a pro-tumor ecosystem.

Perhaps the most consequential discovery concerns what these reprogrammed cells actually do. The researchers found that MAIT_SR cells were a dominant cellular source of CCL20, a chemokine, or chemical messenger, that attracts other immune cells expressing its receptor, CCR6. Using orthotopic liver cancer models, in which tumors are established in the liver of experimental animals, the team assessed the relationship between the CCL20–CCR6 axis and microvascular invasion in vivo. The results were compelling: administration of CCL20 was associated with increased MVI progression, whereas pharmacological blockade of CCR6 reduced the formation of microvascular invasion. This established the chemokine axis not merely as a correlate but as a functional driver of the invasive phenotype, at least in the experimental setting.

The mechanism by which MAIT_SR cells promote immunosuppression was further dissected through spatial analysis and functional assays. The stress-responsive MAIT cells were found to localize to peritumoral regions, the tissue immediately surrounding the tumor, where they recruited CD4-positive T cells via the CCL20–CCR6 axis. Rather than simply attracting any immune cells, however, the MAIT_SR cells actively shaped the fate of their recruits. Through the secretion of transforming growth factor beta 1, or TGF-β1, a potent immunoregulatory cytokine, they drove the differentiation of the recruited CD4-positive T cells into regulatory T cells, or Tregs. Tregs are the immune system’s brakes, cells whose physiological role is to suppress excessive immune responses but which, in cancer, are co-opted by tumors to shield malignant cells from immune attack. The study thus delineates a MAIT_SR–CCL20/TGF-β1–CD4-positive T cell axis that links stress signaling to the construction of an immunosuppressive peritumoral niche.

Beyond the mechanistic insights, the work carries potential therapeutic implications, which the researchers explored directly. In their animal models, two pharmacological interventions showed efficacy in reducing microvascular invasion: blockade of the CCR6 receptor using specific antagonists, and treatment with Acetyl-6-formylpterin, abbreviated Ac-6-FP, a compound that acts on the MR1-dependent antigen presentation pathway central to MAIT cell biology. The finding that Ac-6-FP reduced MVI formation suggests that modulating MAIT cell function through their cognate antigen-presenting molecule may be a viable strategy, while CCR6 antagonism offers a more downstream approach to sever the communication between stress-responsive MAIT cells and the CD4-positive T cells they recruit. Both strategies, if they can be translated safely to patients, would target the peritumoral niche rather than the tumor cells themselves, a conceptually distinct approach from conventional cytotoxic therapy.

The clinical significance of these findings rests on the central problem of postoperative recurrence in hepatocellular carcinoma. Even when tumors are completely resected, patients whose tumors show microvascular invasion face a substantially elevated risk of the disease returning, often within the remnant liver. Because MVI is frequently only detectable by pathological examination after surgery, clinicians currently lack effective tools to prevent vascular dissemination prospectively. If the MAIT_SR–CCL20/TGF-β1 axis proves to be a robust biomarker or a druggable pathway in human patients, it could open a window for perioperative interventions aimed at suppressing the immunosuppressive niche before tumor cells exploit it. The identification of a dominant CCL20-producing immune cell population also adds to a growing appreciation that unconventional T cells can undergo functional rewiring in tumors, a theme that has emerged repeatedly in recent cancer immunology research.

As with any translational study, important caveats apply. The association between stress-responsive MAIT cells and microvascular invasion was established through correlative analyses in human specimens combined with mechanistic work in animal models, and the efficacy of CCR6 antagonists and Acetyl-6-formylpterin was demonstrated in preclinical orthotopic models rather than in clinical trials. The authors themselves frame the findings as supporting a link between stress signaling and the peritumoral immunosuppressive niche, and as suggesting actionable therapeutic strategies, language that appropriately acknowledges the distance between mouse models and human medicine. Nevertheless, the convergence of single-cell transcriptomics, spatial mapping, flow cytometry, multiplex immunohistochemistry, and in vivo pharmacology provides an unusually comprehensive evidentiary foundation. For a disease in which vascular invasion quietly seals the fate of many surgical patients, the identification of a stress-responsive immune axis that can be pharmacologically interrupted represents a genuinely promising lead, and one that the field of hepatocellular carcinoma research will be watching closely as these findings move toward clinical validation.

Subject of Research: The role of stress-responsive MAIT cells in immunosuppression and microvascular invasion in hepatocellular carcinoma

Article Title: Stress-responsive MAIT cells are associated with immunosuppressive microenvironment and microvascular invasion in hepatocellular carcinoma

Article References: Huang, H., Xu, B., Zhang, G., Ye, D., Liao, B., Nong, Z., Guan, Y., Hu, L., Wang, X., & Li, S. (2026). Stress-responsive MAIT cells are associated with immunosuppressive microenvironment and microvascular invasion in hepatocellular carcinoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09071-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09071-4

Keywords: hepatocellular carcinoma, MAIT cells, microvascular invasion, tumor microenvironment, CCL20, CCR6, TGF-β1, regulatory T cells, single-cell RNA sequencing, immunosuppression, heat shock proteins, Acetyl-6-formylpterin

The study, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, tackles a question that immunologists have rarely been able to address directly in human tissue: does the way a T cell generates and uses energy determine whether it mounts an effective attack or slides into exhaustion? Exhaustion is a state in which a cell, activated too long and too continuously, stops responding to the threats it was designed to destroy. Checkpoint immunotherapy, such as antibodies against the PD-1 receptor, releases one of the brakes holding those cells back. For some patients the effect is dramatic; for many others it fails, and the reasons have remained stubbornly unclear.

Metabolism has long seemed a plausible place to look for answers. An immune cell’s capacity to act — to proliferate, to produce inflammatory signals, to kill tumor cells — is constrained by how it generates energy and building blocks. But probing that relationship in human tumors has been technically formidable. The standard laboratory method for measuring cellular metabolism requires a large, pure population of a single cell type, something that is nearly impossible to obtain from a biopsy. As first author Sujeetha A. Rajakumar, Ph.D., a former research associate in the Department of Otolaryngology–Head and Neck Surgery at Johns Hopkins Medicine, explains, what arrives from the clinic is a mixture, there is not much of it, and the cells researchers most want to study are often the rarest. Most of what the field knows about immune cell metabolism has therefore come from mouse tissue and cells grown in dishes, systems that do not always faithfully reflect what happens inside a patient.

The Johns Hopkins team circumvented this bottleneck by measuring each cell’s metabolic machinery alongside the surface markers that identify it. This approach allowed them to read three things from a single cell simultaneously: which cell type it is, what functional state it is in, and what metabolic profile it uses. They applied the method to several populations of tumor-infiltrating immune cells, including mucosal-associated invariant T (MAIT) cells, conventional CD8+ T cells, and innate lymphoid cells (ILCs). Because the technique works on scarce and mixed samples, it opened a window onto metabolic states that had previously been invisible in human tumor tissue.

The tumor samples came from patients enrolled in two phase II clinical trials at Johns Hopkins Medicine in which immunotherapy was administered before surgery. Participants received either the anti-PD-1 antibody nivolumab alone or nivolumab combined with an antibody against interleukin-8, a signaling protein that recruits immune cells to sites of inflammation and infection. Tissue was collected before immunotherapy began and again four weeks later at the time of surgery, giving the investigators a rare opportunity to observe how the immune and metabolic states of individual cells changed within the same patients over the course of treatment.

Three findings stood out. First, the team identified a population of T cells within these tumors that proved to be metabolically fitter and less exhausted than their neighbors, suggesting that not all tumor-infiltrating lymphocytes are equally depleted and that metabolic state tracks closely with function. Second, the more exhausted cells showed elevated levels of the enzyme glucose-6-phosphate dehydrogenase, or G6PD, the rate-limiting enzyme of a metabolic pathway those cells appear to rely on — making it a possible point of intervention. Third, a subset of innate lymphoid cells carried a metabolic profile associated with immune suppression, raising the possibility that these cells may actively pose an obstacle to checkpoint therapy rather than merely failing to help it.

To test whether the exhausted cells truly depend on the G6PD pathway, the researchers turned to laboratory cultures of tumor-infiltrating CD8+ T cells from a separate group of untreated patients. They sorted the cells according to their expression of CD39, a protein that can contribute to immunosuppression by limiting the activation of T cells. The cultures were then treated with a G6PD inhibitor, with an anti-PD-1 antibody, with both, or with neither. The combination treatment produced the largest gene expression changes in the most exhausted cells and increased their secretion of CD27, a marker of T-cell activation. In other words, the cells that seemed least reachable by conventional immunotherapy were the ones that changed the most when the metabolic pathway was blocked alongside checkpoint blockade.

Senior author Martin Alphonse, Ph.D., an assistant professor of dermatology at the Johns Hopkins University School of Medicine, frames the work around a deceptively simple question: take a piece of head and neck tumor tissue and you will find immune cells inside it whose sole purpose is to recognize something abnormal and destroy it — so what has happened to them? The answer emerging from this study is that part of what has happened is metabolic. Exhausted cells appear to have rewired their energy production in a way that can be mapped, and at least one node of that rewiring can be targeted in the laboratory to partially restore function. Rajakumar notes that when the pathway was blocked alongside checkpoint inhibitor treatment, the cells expected to be least reachable changed the most and became reactivated — evidence, she says, that the pathway is worth pursuing.

The clinical context makes the work consequential. Head and neck squamous cell carcinoma, which arises from the cells lining the mouth, throat and voicebox, is the seventh most common cancer worldwide, with roughly 890,000 new cases each year. With checkpoint inhibitors helping fewer than a quarter of these patients, any strategy that could expand the fraction of responders would address a major unmet need. Growing evidence has suggested that metabolic reprogramming influences whether a T cell mounts an effective response or becomes exhausted, but this study is among the relatively few to examine that link directly in human tumor tissue rather than in animal models or cell lines, and to do so across multiple immune cell types at single-cell resolution.

The researchers and their collaborators are careful to stress what the findings are and what they are not. Blocking G6PD in laboratory cultures reactivated exhausted cells, but no patient in the trials received a G6PD inhibitor, and the approach should not be considered a treatment itself. Alphonse emphasizes that these findings need confirmation in larger patient groups before anything can be built on them. The next steps, he says, are to reproduce the results in independent cohorts and to test whether interfering with this metabolic step has any effect in a living system, not just in a dish. Additional co-authors are Namya Nanda, Chloe Kim, Dustin Dikeman, Tanguy Y. Seiwert, Zubair Khan and Sewon Kang, all affiliated with Johns Hopkins Medicine. Study co-author Carole Fakhry, M.D., M.P.H., senior associate dean for clinical affairs at Johns Hopkins, underscores that such interdisciplinary, collaborative studies are critical to understanding how to make therapies more effective in the future, leveraging the translational capabilities of clinical trials to generate insights that laboratory work alone cannot provide. The work was supported by the Johns Hopkins Department of Dermatology, a Career Development Award from the Dermatology Foundation, the Department of Otolaryngology–Head and Neck Surgery, and the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Alphonse and Rajakumar are inventors on two provisional patent applications related to the work, assigned to The Johns Hopkins University, which manages these relationships under its conflict-of-interest policies.

Subject of Research: Immunometabolic profiling of exhausted tumor-infiltrating T cells in head and neck squamous cell carcinoma

Article Title: Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Article References: Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: head and neck cancer, T cell exhaustion, immunotherapy, checkpoint inhibitors, G6PD, tumor metabolism, CD8+ T cells, innate lymphoid cells, MAIT cells, nivolumab, single-cell profiling, Cancer Immunology Research